Administration of secretin (RG1068) increases the sensitivity of detection of duct abnormalities by magnetic resonance cholangiopancreatography in patients with pancreatitis

What Was Tested

This randomized controlled trial paper looks at Secretin.

The researchers performed a large prospective study to investigate whether synthetic human secretin (RG1068)-stimulated MRCP detects pancreatic duct abnormalities with higher levels of sensitivity than MRCP.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

The researchers performed a phase 3, multicenter, baseline-controlled study of patients with acute or acute recurrent pancreatitis who were scheduled to undergo endoscopic retrograde cholangiopancreatography (ERCP) between March 26, 2008, and October 28, 2009.

Patients underwent a baseline MRCP that was immediately followed by administration of RG1068 and repeat MRCP and then underwent ERCP within 30 days; they were followed up for 30 days.

How the Study Was Run

The design is described as randomized and multicenter.

Random assignment meant chance, not the researchers, decided who got Secretin and who got the comparison, which limits bias.

Running at several centres spread the Secretin study over different clinics and patient groups.

The timeline in the abstract includes 30 days.

MRCP and ERCP images were read centrally by 3 radiologists and 2 endoscopists, respectively, who were all independent and blinded; pancreatic duct abnormalities were evaluated.

The accuracy of MRCP was evaluated using ERCP as the standard.

What Was Measured

PubMed files the paper under topics including Acute Disease, Canada, Cholangiopancreatography, Endoscopic Retrograde, Cholangiopancreatography, Magnetic Resonance, Pancreatic Ducts, Pancreatitis and Predictive Value of Tests.

The authors tagged it with the keywords Direct Comparison, Increasing Resolution, Pancreas and Peptide Hormone.

What This Means in Plain Language

The paper is a randomized and multicenter study of Secretin over 30 days.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2014 (Gastroenterology), a journal based in United States.

More context: the Secretin compound page, all human trials.